Intrathecal bupivacaine monotherapy in patients with chronic refractory localized pain: a case series.
Salim Michel Hayek, Cham Alsalak
✦ AI-curated · Sources linked
Case in brief
This case series examined five patients with chronic localized pain who received intrathecal bupivacaine monotherapy after device implantation. All patients had a history of pain management, with some previously on opioid therapy. Following the transition to bupivacaine monotherapy, each patient reported at least 50% pain relief and successfully discontinued systemic opioids.
Diagnostic / clinical pearl
Intrathecal bupivacaine monotherapy can provide significant pain relief in patients with chronic localized pain, allowing for the discontinuation of systemic opioids.
Why it matters
This case series highlights the potential of bupivacaine monotherapy in managing chronic pain, suggesting a need for further research to confirm its safety and efficacy.